Themis Bioscience forms an Exclusive License and Research Alliance with
MSD to Develop Vaccines
Themis Bioscience, a vaccine development firm, has collaborated with the MSD, a trademark company of the Merck. The agreement is an exclusive license with MSD for the discovery and development of measles vaccines to fight cancer. Under the terms of the agreement, Themis will advance the development of the vaccines against a specific disease which remains undisclosed. MSD, on the other hand, will be providing funding and investment in Themis. The collaboration will enable Themis eligible for obtaining development and sales milestone payments of approximately USD 200 milli...
